Kythera files for $86.3m IPO to fund US Phase III studies for chin-thinner
This article was originally published in Scrip
Executive Summary
On the back of positive news regarding its injectable drug to reduce unwanted chin fat, aesthetic medicine specialist Kythera Biopharmaceuticals filed for an $86.3 million initial public offering on 17 May.